Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Average Rating of “Moderate Buy” by Brokerages

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has earned an average recommendation of “Moderate Buy” from the twenty-six research firms that are presently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold recommendation, nineteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $463.1326.

A number of analysts recently commented on ALNY shares. Truist Financial lowered their price objective on Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating for the company in a research report on Monday, April 13th. Canaccord Genuity Group raised their target price on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Jefferies Financial Group reiterated a “hold” rating and set a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a research report on Monday, March 16th. Citigroup initiated coverage on shares of Alnylam Pharmaceuticals in a research note on Tuesday. They set a “buy” rating and a $380.00 price target for the company. Finally, Chardan Capital restated a “buy” rating and issued a $425.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 25th.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 1,652 shares of the company’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $319.73, for a total transaction of $528,193.96. Following the sale, the executive vice president owned 21,860 shares in the company, valued at approximately $6,989,297.80. This represents a 7.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Tolga Tanguler sold 1,598 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $327.65, for a total transaction of $523,584.70. Following the completion of the sale, the executive vice president owned 36,606 shares of the company’s stock, valued at approximately $11,993,955.90. This represents a 4.18% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 21,255 shares of company stock worth $6,930,337 in the last quarter. Company insiders own 0.86% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Mediolanum International Funds Ltd acquired a new position in Alnylam Pharmaceuticals during the third quarter valued at approximately $11,389,000. Rakuten Investment Management Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $14,205,000. Perpetual Ltd acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $2,004,000. Vanguard Group Inc. increased its stake in shares of Alnylam Pharmaceuticals by 2.0% in the 3rd quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock valued at $6,185,846,000 after purchasing an additional 268,313 shares during the last quarter. Finally, iA Global Asset Management Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 979.5% during the 4th quarter. iA Global Asset Management Inc. now owns 17,780 shares of the biopharmaceutical company’s stock worth $7,070,000 after buying an additional 16,133 shares in the last quarter. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY opened at $294.30 on Wednesday. The firm has a market capitalization of $39.29 billion, a PE ratio of 80.41 and a beta of 0.31. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94. Alnylam Pharmaceuticals has a 1-year low of $284.19 and a 1-year high of $495.55. The business’s 50 day moving average is $312.56 and its 200-day moving average is $362.08.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, beating the consensus estimate of $0.87 by $1.12. The business had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.Alnylam Pharmaceuticals’s quarterly revenue was up 96.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.44) EPS. Sell-side analysts predict that Alnylam Pharmaceuticals will post 7.36 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.